AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04955756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Description: Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
Study NCT03586414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MITOQUINOL MESYLATE then placebo
Description: MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
Study NCT03586414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo, then MITOQUINOL MESYLATE
Description: 'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
Study NCT06279156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: Measure BIA for patients' dry weight to compare between measuring every-1-month or every-2-month.~In brief, BIA is the machine used for measure body components such as fat, muscle, and free water. It relies on the principle of using the multifrequency of low electric currents to the body and measurement of the ability of the electrical currents passing different body composition. Thus, the machine can calculate back for the amount of each body composition.
Study NCT06329167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daphnetin
Description: 150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.
Study NCT06329167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aescuven
Description: 150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
Study NCT05382975 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CSPAP-T
Description: Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning
Study NCT04889300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Possible Self
Description: Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
Study NCT04889300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical Day
Description: Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
Study NCT05583929 — intervention group
Intervention type: OTHER
Intervention: GAITRite gaitway system, Bertec Balance System
Description: GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
Study NCT05382637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
Study NCT05754814 — intervention group
Intervention type: OTHER
Intervention: Malignant lymph nodes
Description: Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
Study NCT06239987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care-oriented Practical Training
Description: The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.
Study NCT05403918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Hot pack, TENS, and therapeutic ultrasound will be applied for 10 minutes. Then glides will be given 30 x 3 times in grades III and IV. The rest of the exercises will be prescribed as 3 sets for 10 repetitions with 2 minutes of rest between sets for 6 weeks with respect to 3 sessions per week.
Study NCT05403918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular stabilization exercises along with conventional physiotherapy
Description: Each stretch will be repeated 3 times. Each active exercise will be progressed from 3 sets of 10 reps to 3 sets of 15 reps. If the subject easily completed 3 sets of 15 reps of active exercise, they will go on to resisted exercises. These will be performed once a day, for 6 weeks, 3 sessions per week.
Study NCT05648279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized hemodynamic management
Description: Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
Study NCT04920669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block with bupivacaine
Description: Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
Study NCT04920669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block with bupivacaine + dexmedetomidine
Description: Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine
Study NCT05006469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, >70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
Study NCT05366686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NICE Support Program
Description: Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
Study NCT05364242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
Study NCT04677244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample in portal vein
Description: A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.
Study NCT04670926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
Study NCT05804708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH001
Description: GH001 is administered via inhalation
Study NCT04699487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Oral pads will be applied on irradiated areas presenting a risk of radiotherapy-related OM. In addition, a derma pad will be applied on the anterior face of the neck to protect the oropharynx from OM.~The dose to be delivered, at each session and each applied area, has been set at 3 J/cm². In case a lesion appears, the dose will be increased to 6J/cm² for curative treatment.~Treatment with CareMin650 must start on the first day of radiotherapy and will be administered during the whole radiotherapy period, ideally 5 days/week, at least 3 days/week, ideally before the radiotherapy session.
Study NCT05148923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct current cardioversion (DCCV)
Description: DCCV is a safe and effective method of treating atrial fibrillation.
Study NCT05352152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequence
Description: Next generation sequence will be used to detect the pathogens in ascites.
Study NCT05598099 — intervention group
Intervention type: BEHAVIORAL
Intervention: Concentrated cognitive behavioral therapy
Description: A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
Study NCT06341920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: BoneFit intervention
Description: Exercise, nutrition and psychological support provided in 8 weeks prior to surgery
Study NCT06341920 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control
Description: Control group receive usual care (zero intervention)
Study NCT04829435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-346
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
Study NCT06294457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Neuromodulation NESA
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.
Study NCT06294457 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Invasive Neuromodulation NESA
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.
Study NCT04795557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ADAPT-232 oral solution
Description: One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients
Study NCT04795557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Excipients
Study NCT05618821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
Study NCT05618821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
Study NCT04839380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib cream
Description: ruxolitinib cream 1.5% will be applied twice daily as a thin film
Study NCT04697485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
Description: Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg
Study NCT05082103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme lozenge 1
Description: Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
Study NCT05082103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme lozenge 2
Description: Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
Study NCT05082103 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge
Description: Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
Study NCT05344521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integra®
Description: A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).
Study NCT05344521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra®-SC
Description: A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
Study NCT06494137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inulin
Description: inulin from chicory root
Study NCT06494137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: inulin from chicory root
Study NCT04829435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Study NCT05225402 — intervention group
Intervention type: DRUG
Intervention: Hemodynamic measurements during reduction in Norepinephrine and fluid boli.
Description: 1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP.
Study NCT04733690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Common bean product
Description: Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected
Study NCT06199388 — intervention group
Intervention type: OTHER
Intervention: Survival state
Description: We recorded clinically relevant information and survival status of pediatric glioma patients
Study NCT05841823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRET)
Description: The relaxation scene includes four beautiful landscapes, and patients can choose any of these four, as perceived to be the most comfortable landscape. The visual stimulation of high-risk scene is designed as any combination of four different scenes (street barbecue stands, restaurant, bar and home) and four kinds of alcoholic beverages (Chinese liquor, beer, grape wine and cocktail), which are customized according to the patient's personal preference. At the same time, the odor of the alcoholic beverage of the patient's choice will be provided as an olfactory stimulation. The aversive situation will be the visual and auditory stimulation provided by a video of an alcoholic vomiting, while olfactory stimulation will be provided by cotton balls soaked in fermented dairy products.
Study NCT05841823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy (ACT)
Description: The initial session began with case formulation. Subsequent sessions involved learning on acceptance and acknowledgement of unpleasant thoughts and feelings associated with alcohol craving and clinical features of alcohol use disorder, cognitive defusion on how to dissociate self avoidance of unpleasant thoughts and feelings, learning and practicing mindfulness exercise (such as mindfulness breathing) to make self aware of the many things that occurred presently which can be enjoyed and focus on rather than focusing on unpleasant thoughts and feelings, and learning to be aware of the safe self which is separated from the unpleasant thoughts and feelings and identifying values in life and strategies to achieve these values (therapeutic processes in hexaflex).
Study NCT04807348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar 32mg
Description: Administrated once daily
Study NCT04807348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar 48mg
Description: Administrated once daily
Study NCT04807348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Chiglitazar
Study NCT04807348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: most tolerable dose
Study NCT04807348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Hydrochloride
Description: most tolerable dose
Study NCT05858619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: dupilumab 600 mg injection initially and then 300 mg every other week
Study NCT06203561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
Study NCT06203561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
Study NCT06203561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.
Study NCT06203561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.